Trials / Terminated
TerminatedNCT02228811
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
Detailed description
This is a first-in-human study of DCC-2701. The primary purpose of this study is to determine what dose of DCC-2701, can be given safely to patients with advanced solid tumors. The study will have two phases. The first phase will assess escalating doses of DCC-2701 in order to determine the maximally tolerated dose (MTD) and the optimal dosing regimen (ODR) of DCC-2701. Once the MTD and ODR is established, a dose expansion phase will further evaluate the safety of DCC-2701, as well as the activity of DCC-2701 in select solid tumor types.
Conditions
- Locally Advanced Tumors
- Metastatic Solid Tumors
- Cancers With MET Genomic Alterations
- Cancers With TRK Genomic Alterations
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCC-2701 tablet |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-11-01
- Completion
- 2018-01-01
- First posted
- 2014-08-29
- Last updated
- 2018-02-01
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02228811. Inclusion in this directory is not an endorsement.